Synthra MeIPlus Research with HCN/CO Options and Radchrom Plus for the UAB Cyclotron Facility

项目摘要 本提案寻求支持，以采购和安装一台新的放射性药物合成器（Synthra Radchrom Plus）能够生产用于临床前（小动物成像）研究和阶段研究的11 C放射性标记药物 0/I/II临床试验的成像研究人员。碳-11显像剂对于许多NIH和 其他联邦和基金会资助的研究在UAB和由于短半衰期的11 C，合成这些 代理必须在现场进行。该模块将安置在UAB回旋加速器设施内，并进行维护和 由训练有素的技术人员操作。位于伯明翰的亚拉巴马大学 投资于分子成像基础设施，包括TR 24回旋加速器、PET/CT和PET MRI 扫描仪和完整的GMP放射性药物生产设施，包括独立的放射性药物。作为 使用11 C化合物的研究在UAB大大扩展，新模块将使 11 C成像剂的入组和稳定可用性。为了保持和扩大我们目前的 高质量的研究水平，并继续取得新的进展，收购Synthra Radchrom Plus对至少8名NIH资助的研究人员和其他一些研究人员至关重要，包括 高级和早期调查员的组合。新的合成器将支持广泛的11 C标记 方法包括直接标记格氏试剂（如用于制备11 C-乙酸酯）， 将11 C-CO2转化为11 C-甲烷、11 C-碘甲烷和/或11 C-三氟甲磺酸甲酯，可用于 对NIH资助的研究很重要的示踪剂，如用于成像的11 C-匹兹堡化合物B（[11 C]PiB） 脑中淀粉样蛋白沉积和11 C-UCB-J，用于成像突触囊泡糖蛋白2A（SV 2A）密度 神经退行性疾病的患者。该建议得到了大学的大力支持， 来自各个部门和中心的专用空间和大量资金（30，000美元），以帮助支持这一点 进步。继续支持目前正在进行的项目，同时扩大和扩大能力， 培育新项目是本申请的最终目标。

Project Summary This proposal seeks support to procure and install a new radiopharmaceutical synthesizer (Synthra Radchrom Plus) capable of producing 11C-radiolabeled drugs for preclinical (small animal imaging) studies and for Phase 0/I/II clinical trials for imaging researchers. Carbon-11 imaging agents are essential for multitude of NIH and other federal and foundation funded research at UAB and due to the short half-life of 11C, the synthesis of these agents must occur onsite. The module will be housed within the UAB cyclotron facility and maintained and operated by highly trained technical staff. The University of Alabama at Birmingham has made significant investments in the infrastructure of molecular imaging including a TR24 cyclotron, PET/CT and PET MRI scanners and a full GMP radiopharmaceutical production facility including a standalone, radiopharmacy. As research studies using 11C compounds have greatly expanded at UAB, the new module will enable the onboarding and robust availability of 11C-imaging agents. In order to maintain and expand upon our current level of high-quality research and to continue to make novel advancements, the acquisition of the Synthra Radchrom Plus is critical for at least 8 NIH funded researchers and a number of additional researchers including a mix of senior and early stage investigators. The new synthesizer will support a wide range of 11C-labeling methods including direct labeling of Grignard reagents (such as for the preparation of 11C-Acetate) and conversion of 11C-CO2 to 11C-Methane, 11C-Methyl iodide and/or 11C-Methyl Triflate, which can be used for a tracers important for NIH funded research such as, 11C-Pittsburgh Compound B ([11C]PiB) used for imaging of amyloid deposition in the brain and 11C-UCB-J, used for imaging synaptic vesicle glycoprotein 2A (SV2A) density in patients with neurodegenerative disease. This proposal is being strongly supported by the University with dedicated space and significant funds ($30,000) from a variety of departments and centers to help support this advancement. Continued support of current ongoing projects, while broadening and extending capabilities to foster new projects is the ultimate goal of the present application.